INIS
kazakhstan
100%
patients
82%
tuberculosis
80%
genetics
76%
genes
61%
risks
49%
populations
39%
data
35%
genotype
34%
drugs
32%
mutations
30%
humans
28%
women
24%
mycobacterium tuberculosis
23%
variations
22%
vitamin d
21%
diseases
20%
strains
20%
host
20%
control
19%
cancer
18%
levels
17%
length
15%
epidemiology
14%
telomeres
14%
epilepsy
14%
death
13%
testing
12%
metabolism
11%
evaluation
11%
receptors
11%
values
11%
heart failure
10%
children
10%
viruses
9%
reviews
8%
infectious diseases
8%
rna
8%
assessments
7%
asia
7%
people
7%
biological markers
7%
surgery
7%
fever
7%
carcinomas
7%
esophagus
7%
vaccines
7%
devices
7%
homocysteine
7%
collagen
7%
hepatitis
7%
diet
7%
distribution
7%
breasts
7%
angiotensin
7%
enzymes
7%
cardiovascular diseases
7%
chromosomes
7%
cytology
7%
liver cirrhosis
7%
bypasses
7%
resources
7%
lactobacillus
7%
carboxylesterases
7%
corrections
7%
infants
7%
antibiotics
6%
information
6%
comparative evaluations
6%
screening
6%
nucleotides
5%
origin
5%
mortality
5%
Keyphrases
Kazakhstan
72%
Whole Genome Sequencing
30%
Tuberculosis
29%
Mycobacterium Tuberculosis (M. tb)
26%
Pulmonary Tuberculosis
21%
Polymorphism
16%
Tuberculosis Epidemiology
15%
Kazakh
14%
Telomere Length
14%
Whole Genome
13%
Genotype
11%
Whole-genome Sequence Data
10%
Central Asia
9%
Genetic Profile
9%
Genomic Variants
9%
Genetic Variants
9%
Metabolism
8%
Life Expectancy
8%
Genetic Variation
8%
Host Genetics
8%
Mycobacterium Tuberculosis Strains
8%
Drug Resistance
8%
Genetic Polymorphism
7%
High Risk
7%
High-risk Human Papillomavirus Infection
7%
Sequence Variants
7%
Sputum
7%
MIRU-VNTR Genotyping
7%
Patients with Breast Cancer
7%
Kazakh Patients
7%
Draft Genome Sequence
7%
TLR Polymorphism
7%
VDR Polymorphism
7%
SARS-CoV-2 Genome
7%
Salivaomics
7%
Multidrug-resistant Mycobacterium Tuberculosis
7%
Genotype Distribution
7%
Abnormal Cervical Cytology
7%
Body Mass Evolution
7%
Stapleless
7%
Gastric Bypass
7%
Laparoscopic Roux-en-Y Gastric Bypass (LRYGB)
7%
Hypocaloric Diet
7%
XDR-TB
7%
Heart Failure Patients
7%
Vitamin D Pathway
7%
Esophageal Squamous Cell Carcinoma
7%
Haplogroup
7%
Homocysteine Levels
7%
Viral Infection
7%
Genetic Determinants
7%
Innate Immune Response
7%
Omics Technologies
7%
Length Change
7%
Amplicon
7%
COVID-19
7%
Vitamin D Status
7%
Congestive Heart Failure
7%
Olympics
7%
Cardiointervalography
7%
Stress Testing
7%
12-lead
7%
Sequence-based
7%
Randomized Controlled Trial
7%
Bariatric
7%
Variation Analysis
7%
Oxford Nanopore
7%
Metabolic Syndrome
7%
Oxford Nanopore Sequencing
7%
Genomic Analysis
7%
Left Ventricular Assist Device
7%
XDR Strains
7%
Sudden Cardiac Death
7%
Human Papillomavirus Genotypes
7%
Cardiovascular System
7%
Functional Assessment
7%
AutoML
7%
Active Tuberculosis
7%
Risk Prediction
7%
Risk of Progression
7%
Tuberculosis Infection
7%
Direct Oral Anticoagulants
7%
Carboxylesterase 1 (CES1)
7%
Stepfathers
7%
Epidemiological Aspects
7%
Genetic Aspects
7%
Surnames
7%
Molecular Neuroscience
7%
Homozygous Familial Hypercholesterolemia (HoFH)
7%
Epilepsy Syndrome
7%
Novel mutation
7%
Chrna2
7%
Dabigatran
6%
Virus
5%
SNP
5%
High-risk Human Papillomavirus (HR-HPV)
5%
SNP Markers
5%
Cardiovascular Disease
5%
HPV16
5%
Bariatric Surgery
5%
Biochemistry, Genetics and Molecular Biology
Genotyping
44%
Genetics
37%
Whole Genome Sequencing
37%
Mycobacterium Tuberculosis
24%
Single Nucleotide Polymorphism
18%
Genetic Divergence
18%
Next Generation Sequencing
15%
Drug Resistance
14%
Telomere Length
14%
Ventricular Tachycardia
14%
Variable Number Tandem Repeat
12%
Prevalence
10%
Single-Nucleotide Polymorphism
10%
Life Expectancy
9%
Genetic Polymorphism
9%
Case-Control Study
8%
Haplogroup
8%
Genetic Variation
7%
Survival Rate
7%
Liquid
7%
Enzyme Polymorphism
7%
Telomere
7%
Angiotensin-Converting Enzyme
7%
SARS Coronavirus
7%
Randomized Controlled Trial
7%
Body Mass
7%
Amplicon
7%
Hepatitis Virus
7%
Homocysteine
7%
Hypovitaminosis D
7%
Lactobacillus casei
7%
Carboxylesterase 1
7%
Y Chromosome
7%
Familial Hypercholesterolemia
7%
CHRNA2
7%
Nonsense Mutation
7%
Enterococcus
7%
TLR8
6%
Folic Acid
5%
MARCO
5%
Drug Sensitivity
5%
Real-Time Polymerase Chain Reaction
5%